Stevanato Group Q4 and FY 2025 Financial Results March 4, 2026 Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. ("we", "our", "us", "Stevanato Group" or the "Company") and which involve known and unknown risks, uncertainties and assumptions because they relate to events and depend on circumstances that will occur in ...

Financial Performance - Revenue grew by 8% year-over-year in Q2 2025, driven by a 10% increase in the BDS (Biopharmaceutical and Diagnostic Solutions) segment, offsetting a 2% decline in the Engineering segment[12, 30] - High-Value Solutions (HVS) accounted for 42% of total revenue in Q2 2025[12] and increased 13% year-over-year to €116.8 million[30] - Gross profit margin increased by 210 bps to 28.1%[31] - Adjusted EBITDA increased to €65.1 million, with an adjusted EBITDA margin increase of 240 bps to 23.2%[31] - Net profit was €29.7 million, or €0.11 of diluted EPS[31] Segment Performance - BDS segment revenue increased by 10% to €244 million, with a gross profit margin increase of 350 bps to 31.2%[33, 34, 35] - Engineering segment revenue decreased by 2% to €36.5 million, with a gross profit margin decrease to 6.6%[36, 37] Capacity Expansion and Investments - Capital expenditure (CAPEX) in Q2 2025 was €69.1 million[40] - Net cash generated from operations in Q2 2025 was €44.9 million[40] - Free cash flow in Q2 2025 was negative €13.0 million[40] - The company announced financing agreements totaling €200 million to support capacity expansion in Latina and Fishers facilities[40] Outlook - The company maintains its FY 2025 revenue guidance of €1.160 billion - €1.190 billion, representing a year-over-year growth of 5% to 8%[42] - The company expects HVS to account for 40% to 42% of revenue in FY 2025[42] - Adjusted diluted EPS is projected to be €0.50 - €0.54 for FY 2025[42] - Adjusted EBITDA is projected to be €288.5 million - €301.8 million for FY 2025[42]

Q1 2025 Financial Performance - Revenue increased by 9% to €256.6 million, driven by an 11% growth in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, offsetting a 4% decline in the Engineering segment[27, 30, 36, 57] - High Value Solutions (HVS) increased 25% year-over-year to €110 million, representing 43% of total revenue, fueled by strong demand for high-value PFS and a partial recovery in EZ-fill® vials[12, 30] - Adjusted EBITDA increased 13% to €57.4 million, with the adjusted EBITDA margin increasing 100 bps to 22.4%[31] - Net profit was €26.5 million, or €0.10 of diluted EPS, while adjusted net profit was €28.1 million, or €0.10 of adjusted diluted EPS[31] Segment Trends - BDS segment revenue increased 11% to €221 million, with a gross profit margin increase of 420 bps to 31.3%, driven by improvements in Latina and Fishers facilities and a higher mix of accretive HVS[33, 34] - Engineering segment revenue decreased 4% to €35.7 million, with a gross profit margin decrease to 10.7%, impacted by project mix as the company prioritized the completion of legacy projects in Denmark[35, 36] Balance Sheet and Cash Flow - Total cash and cash equivalents stood at €90.7 million, with net debt at €300.2 million[39] - Capital expenditures (CAPEX) amounted to €69.7 million, with net cash generated from operations at €99.8 million and free cash flow at €29.7 million[39] FY 2025 Guidance - Revenue is projected to be between €1.160 billion and €1.190 billion, implying a revenue growth of 5% to 8%[41] - Adjusted diluted EPS is expected to be between €0.50 and €0.54, with adjusted EBITDA between €288.5 million and €301.8 million[41]